Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Gilead Sciences Incorporated
Woman and Man Max 99 years
Gilead Sciences Incorporated
Update Il y a 5 ans
A Phase IIa, Double-blind, Randomised, Placebo-Controlled Dose Escalation Study to Evalulate the Safety, Tolerability, Pharmacokinetics and Activity of GS-9450, a Caspase Inhibitor, in Subjects with Chronic Hepatitis C
• To investigate the safety and tolerability of multiple oral doses of GS-9450 in subjects with chronic hepatitis C (HCV).
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Gilead Sciences Incorporated
Update Il y a 5 ans
A Phase 2, Randomized, Double-Blind Study Exploring the Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine plus Tenofovir DF Fixed-Dose Combination Therapy in Subjects Currently Being Treated with Adefovir Dipivoxil for Chronic Hepatitis B and having Persistent Viral Replication. Estudio aleatorizado de fase 2 a doble ciego para evaluar la eficacia, seguridad y tolerabilidad de la monoterapia de tenofovir disoproxil fumarato (DF) en comparación con la terapia combinada de emtricitabina más tenofovir DF a dosis fija, en pacientes que reciben adefovir dipivoxil en la actualidad para el tratamiento de la hepatitis B crónica y presentan replicación viral persistente
To characterize the antiviral activity of tenofovir DF 300 mg QD versus emtricitabine 200 mg/tenofovir DF 300 mg QD in subjects currently being treated with adefovir dipivoxil for CHB who have persist...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Gilead Sciences Incorporated
Update Il y a 5 ans
A Double-blind, Randomized, Placebo-controlled Phase 1/2 Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9131 in Antiretroviral-Naive, HIV-1 Infected Subjects
To investigate the safety, tolerability, and antiviral activity of GS-9131 administered orally as ten consecutive once-daily doses in antiretroviral-naive subjects chronically infected with HIV-1.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Gilead Sciences Incorporated
Update Il y a 5 ans
Clinical research study involving an experimental combination medication called EVG/COBI/FTC/TDF. This is 1 pill containing 2 experimental medications, EVG and COBI, plus 2 medications already approved for the treatment of HIV-1 infection, FTC and TDF. In this study neither the patient or the investigator will know whether the patient is receiving EVG/COBI/FTC/TDF or the comparator drug ritonavir-boosted atazanavir with FTC/TDF. This is a randomized (by chance, like a flip of a coin) study
To evaluate the efficacy of a regimen containing elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus emtricitabine/tenofovir disoproxil fumara...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Gilead Sciences Incorporated
Update Il y a 5 ans
A Randomized, Double Blind Study Evaluating Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus the Combination of Emtricitabine and Tenofovir DF for the Treatment of Chronic Hepatitis B
•To compare the antiviral efficacy against hepatitis B virus (HBV) of tenofovir DF monotherapy versus tenofovir DF plus emtricitabine combination therapy
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Gilead Sciences Incorporated
Update Il y a 5 ans
A Phase 2, Double-Blind, Multi-center, Randomized Study Comparing Tenofovir Disoproxil Fumarate, Emtricitabine Plus Tenofovir Disoproxil Fumarate, and Entecavir in the Treatment of Chronic Hepatitis B Subjects with Decompensated Liver Disease and in the Prevention of Hepatitis B Recurrence Post-Transplantation
To evaluate and compare the safety and tolerability of tenofovir disoproxil fumarate, emtricitabine plus tenofovir disoproxil fumarate, and entecavir in the treatment of chronic hepatitis B subjects w...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Gilead Sciences Incorporated
Update Il y a 5 ans
A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Activity of GS 9450 in Adults with Non-Alcoholic Steatohepatitis (NASH)
• To investigate the safety and tolerability of multiple oral doses of GS 9450 in subjects with NASH
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Gilead Sciences Incorporated
Update Il y a 5 ans
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Comparing 24 or 48 Weeks of GS-9190, in Combination with Peginterferon Alfa 2a and Ribavirin, to 48 Weeks of Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic Hepatitis C Virus (HCV) Infection
To compare the early antiviral activity (complete early virologic response rate; cEVR) of GS-9190 versus placebo, in combination with peginterferon alfa 2a (PEG) and ribavirin (RIBA), following 12 wee...
Country
None
organs
None
Specialty
None
unknown
More information
Man Max 99 years
Gilead Sciences Incorporated
Update Il y a 5 ans
A Phase IV, Randomized, Double-Blind, Placebo-Controlled Two-Phase Crossover Study of the Metabolic Impact of Tenofovir Disoproxil Fumarate on HIV 1 Seronegative Healthy Adult Males
To assess the impact on insulin sensitivity (determined by peripheral glucose uptake using a euglycaemic clamp) of the administration of tenofovir DF compared with placebo for two weeks in HIV 1 seron...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Gilead Sciences Incorporated
Update Il y a 5 ans
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Early Idiopathic Pulmonary Fibrosis (IPF)
The primary objective of the study is to determine if ambrisentan is effective in delaying disease progression and death in subjects with IPF.
Country
None
organs
None
Specialty
None
Closed trial
More information
1
2
Next